Hugel, Inc.

145020.KQ

145020.KQHugel, Inc. KR flag

KOSDAQ

337,000.00

KRW

-500.00

(-0.15%)

3.63TMarket Cap

May 07Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7145020004

Return %

Stock

S&P500

85.67

10.92

141.75

26.22

209.18

120.31

Use logarithmic scale

	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	7,231.23	10,233	15,103.3	19,446.54	18,259.73	5,520.5	17,100.74	19,008.93	23,636.77	28,223.95	33,922.11
Basic EPS, GAAP	2,356.72	5,336.07	5,262.59	7,777.86	6,981.5	1,203.91	3,402.68	4,733	4,811	8,217	10,447.84
Free Cash Flow per Basic Share	679.02	1,047.09	3,532.84	6,083.75	4,912.63	1,311.91	2,360.79	3,077.59	2,987.17	6,811.03	5,619.69
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	9.35	- -
Book Value per Share	5,483.84	10,177.52	13,146.1	19,364.17	76,357.94	20,792.71	66,031.31	69,490.07	75,979.39	83,217.28	- -
Tangible Book Value per Share	7,472.48	23,729.85	25,545.67	69,871.6	67,306.69	16,479.76	50,585.12	51,793.09	54,492.4	52,738.15	79,502.48
Basic Weighted Avg Shares	6	6	8	9	10	37	12	12	12	11	11
Sales/Revenue/Turnover	40,350	65,066	124,189	182,085	182,392	204,568	211,038	231,859	281,675	319,700	363,785
Operating Margin (%)	38.38	27.29	50.94	55.98	33.21	33.28	36.99	41.24	35.99	36.84	51.13
Depreciation Expense	608	1,550	4,809	6,762	7,491	9,486	10,704	14,299	13,994	13,860	11,523
Net Income, GAAP	13,150	33,929	43,273	72,827	69,736	44,612	41,992	57,730	57,332	93,076	112,044
Effective Tax Rate (%)	15.79	8.79	20.88	21.44	23.98	27.89	34.64	32.33	12.56	26.72	22.63
Profit Margin (%)	32.59	52.15	34.84	40	38.23	21.81	19.9	24.9	20.35	29.11	30.8
Working Capital	-2,023	89,626	131,437	656,714	661,763	603,343	624,635	562,054	440,550	510,347	500,556
LT Debt	- -	- -	- -	79,572	82,926	89,999	92,322	96,819	1,259	89,915	- -
Total Equity	42,674	215,191	273,940	717,920	784,783	744,271	794,069	829,168	849,454	779,678	852,595
Return on Invested Capital (%)	- -	11.16	19.93	14.7	5.51	5.77	5.92	7.15	9.33	9.23	16.19
Return on Capital (%)	- -	48.71	35.12	31.74	11.19	4.59	4.41	5.89	5.5	8.52	18.49
Return on Common Equity (%)	- -	71.2	50.08	50.33	14.77	5.82	5.3	6.95	6.54	10.07	22.81

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	12.04%	13.5%
Net Income, GAAP	- -	11.45%	62.35%
Free Cash Flow	- -	19.88%	116.73%
Total Cash Common Dividend	- -	- -	- -
Total Equity	- -	0.04%	-8.21%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Ji-hoon Sohn
Full Time Employees: 594
Address: 61-20, Sinbuk-ro Chuncheon-si 24206
IPO Date: Dec 24, 2015
Website: hugel.co.kr
Similar Companies: Iron Horse Acquisitions Corp. Right (IROHR)
Inhibrx, Inc. Ex-distribution When-Issued (INBXV)
Koton Magazacilik (KOTON.IS)
Investeringsforeningen Jutlanderinvest - Konservativ (SDIKON.CO)
Tristar Acquisition I Corp. (TRIS-WT)
WisdomTree Industrial Metals Enhanced (XMWJ.DE)
Business: Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.

	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	7,231.23	10,233	15,103.3	19,446.54	18,259.73	5,520.5	17,100.74	19,008.93	23,636.77	28,223.95	33,922.11
Basic EPS, GAAP	2,356.72	5,336.07	5,262.59	7,777.86	6,981.5	1,203.91	3,402.68	4,733	4,811	8,217	10,447.84
Free Cash Flow per Basic Share	679.02	1,047.09	3,532.84	6,083.75	4,912.63	1,311.91	2,360.79	3,077.59	2,987.17	6,811.03	5,619.69
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	9.35	- -
Book Value per Share	5,483.84	10,177.52	13,146.1	19,364.17	76,357.94	20,792.71	66,031.31	69,490.07	75,979.39	83,217.28	- -
Tangible Book Value per Share	7,472.48	23,729.85	25,545.67	69,871.6	67,306.69	16,479.76	50,585.12	51,793.09	54,492.4	52,738.15	79,502.48
Basic Weighted Avg Shares	6	6	8	9	10	37	12	12	12	11	11
Sales/Revenue/Turnover	40,350	65,066	124,189	182,085	182,392	204,568	211,038	231,859	281,675	319,700	363,785
Operating Margin (%)	38.38	27.29	50.94	55.98	33.21	33.28	36.99	41.24	35.99	36.84	51.13
Depreciation Expense	608	1,550	4,809	6,762	7,491	9,486	10,704	14,299	13,994	13,860	11,523
Net Income, GAAP	13,150	33,929	43,273	72,827	69,736	44,612	41,992	57,730	57,332	93,076	112,044
Effective Tax Rate (%)	15.79	8.79	20.88	21.44	23.98	27.89	34.64	32.33	12.56	26.72	22.63
Profit Margin (%)	32.59	52.15	34.84	40	38.23	21.81	19.9	24.9	20.35	29.11	30.8
Working Capital	-2,023	89,626	131,437	656,714	661,763	603,343	624,635	562,054	440,550	510,347	500,556
LT Debt	- -	- -	- -	79,572	82,926	89,999	92,322	96,819	1,259	89,915	- -
Total Equity	42,674	215,191	273,940	717,920	784,783	744,271	794,069	829,168	849,454	779,678	852,595
Return on Invested Capital (%)	- -	11.16	19.93	14.7	5.51	5.77	5.92	7.15	9.33	9.23	16.19
Return on Capital (%)	- -	48.71	35.12	31.74	11.19	4.59	4.41	5.89	5.5	8.52	18.49
Return on Common Equity (%)	- -	71.2	50.08	50.33	14.77	5.82	5.3	6.95	6.54	10.07	22.81

	Mar'24	Jun'24	Sep'24
ST Debt	2,209	2,222	- -
LT Borrowings	89,888	23,963	- -
LT Finance Leases	12,282	11,776	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	11	11	11
Market Capitalization	2,122,619	2,515,005	2,568,429

	Mar'24	Jun'24	Sep'24
Total Current Assets	526,737	503,549	552,609
Accounts Receivable, Net	26,717	39,502	- -
Cash, Cash Equivalents & STI	451,874	412,434	- -
Inventories	43,952	43,610	- -
Total Current Liabilities	56,502	46,878	52,053
Payables & Accruals	- -	- -	- -
ST Debt	2,209	2,222	- -
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	1,234	1,245	2,175	- -	4,811
2023	1,403	1,870	3,512.77	- -	8,217
2024	1,923	3,272	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	61,644	63,862	70,677	85,492	281,675
2023	64,380	81,556	84,817	88,947	319,700
2024	74,306	95,423	105,109	- -	- -

Hugel, Inc.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year